FDA CRL for relacorilant sparks shareholder probes into Corcept Therapeutics

Regulatory setback for relacorilant spurs shareholder probes into Corcept

Regulatory and legal scrutiny intensifies around Corcept Therapeutics after two national law firms say they are investigating whether the company misled investors following a U.S. Food and Drug Administration decision on its relacorilant application. DJS Law Group and The Schall Law Firm announce separate inquiries focused on potential securities law violations tied to Corcept’s disclosure that the FDA issued a Complete Response Letter (CRL) for relacorilant as a treatment for hypertension secondary to hypercortisolism.

Law firms probe disclosure, seek documents and timing of statements

Both firms state they will review Corcept’s public statements, SEC filings, investor presentations and the timing of disclosures to determine whether executives knew of adverse evidence and failed to inform shareholders. The CRL acknowledges that Corcept’s pivotal GRACE trial meets its primary endpoint and that GRADIENT provides confirmatory data, but the FDA concludes it cannot reach a favorable benefit‑risk assessment without additional evidence of effectiveness. DJS and Schall frame their investigations around whether those regulatory concerns were adequately disclosed to the market and whether investors were given a complete picture of the pathway to approval.

Implications for Corcept’s regulatory strategy and litigation risk

The dual probes underscore the intersection of regulatory uncertainty and corporate disclosure practices in specialty endocrine therapeutics. Corcept is now confronting both the practical challenge of generating further evidence to satisfy the FDA’s effectiveness concerns and potential litigation over the adequacy and timing of its communications. The investigations signal heightened scrutiny of how biopharma companies characterize clinical results and regulatory feedback when pursuing accelerated or challenging approvals in narrow patient populations.

Trials and regulatory context

Relacorilant’s GRACE trial is described by the FDA as meeting its primary endpoint, with GRADIENT data cited as confirmatory, but the agency asks for more evidence to support a favorable benefit‑risk determination for the hypertension indication. That request frames the next steps for Corcept’s development program, which may include additional studies or analyses to demonstrate effectiveness to regulators.

Law firms invite shareholders to participate

Both DJS Law Group and The Schall Law Firm invite shareholders who believe they suffered losses to contact them for potential representation; each firm highlights experience in securities class actions and shareholder rights litigation and notes that the announcements may be considered attorney advertising under some jurisdictions’ rules.